Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/11256
Title: | Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. |
Authors: | Pölzl, Gerhard Altenberger, Johann Baholli, Loant Beltrán, Paola Borbély, Attila Comin-Colet, Josep Delgado, Juan F Fedele, Francesco Fontana, Antonella Fruhwald, Friedrich Giamouzis, Gregory Giannakoulas, George Garcia-González, Martín J Gustafsson, Finn Kaikkonen, Kari Kivikko, Matti Kubica, Jacek von Lewinski, Dirk Löfman, Ida Malfatto, Gabriella Manito, Nicolás Martínez-Sellés, Martin Masip, Josep Merkely, Bela Morandi, Fabrizio Mølgaard, Henning Oliva, Fabrizio Pantev, Emil Papp, Zoltán Perna, Gian Piero Pfister, Roman Piazza, Vito Bover, Ramón Rangel-Sousa, Diego Recio-Mayoral, Alejandro Reinecke, Alexander Rieth, Andreas Sarapohja, Toni Schmidt, Gunter Seidel, Mirko Störk, Stefan Vrtovec, Bojan Wikström, Gerhard Yerly, Patrik Pollesello, Piero |
Keywords: | Advanced heart failure;Clinical trial;Composite end-point;Intermittent;Levosimendan;Repetitive |
metadata.dc.subject.mesh: | Administration, Oral Cardiotonic Agents Clinical Trials as Topic Consensus Development Conferences as Topic Drug Administration Schedule Europe Evidence-Based Medicine Heart Failure Humans Hydrazones Infusions, Intravenous Pyridazines Rome Simendan |
Issue Date: | 23-May-2017 |
Abstract: | Patients in the latest stages of heart failure are severely compromised, with poor quality of life and frequent hospitalizations. Heart transplantation and left ventricular assist device implantation are viable options only for a minority, and intermittent or continuous infusions of positive inotropes may be needed as a bridge therapy or as a symptomatic approach. In these settings, levosimendan has potential advantages over conventional inotropes (catecholamines and phosphodiesterase inhibitors), such as sustained effects after initial infusion, synergy with beta-blockers, and no increase in oxygen consumption. Levosimendan has been suggested as a treatment that reduces re-hospitalization and improves quality of life. However, previous clinical studies of intermittent infusions of levosimendan were not powered to show statistical significance on key outcome parameters. A panel of 45 expert clinicians from 12 European countries met in Rome on November 24-25, 2016 to review the literature and envision an appropriately designed clinical trial addressing these needs. In the earlier FIGHT trial (daily subcutaneous injection of liraglutide in heart failure patients with reduced ejection fraction) a composite Global Rank Score was used as primary end-point where death, re-hospitalization, and change in N-terminal-prohormone-brain natriuretic peptide level were considered in a hierarchical order. In the present study, we tested the same end-point post hoc in the PERSIST and LEVOREP trials on oral and repeated i.v. levosimendan, respectively, and demonstrated superiority of levosimendan treatment vs placebo. The use of the same composite end-point in a properly powered study on repetitive levosimendan in advanced heart failure is strongly advocated. |
URI: | http://hdl.handle.net/10668/11256 |
metadata.dc.identifier.doi: | 10.1016/j.ijcard.2017.05.081 |
Appears in Collections: | Producción 2020 |
Files in This Item:
There are no files associated with this item.
This item is protected by original copyright |
This item is licensed under a Creative Commons License